Reasons for Denial of Data Requests

A full list of Vivli members’ data sharing policies can be found on their member’s page.

 

Reason Data Request Denied: Out of Scope of Data Contributor’s Data Sharing Policy

Data contributorStudies Research ProposalRequest ID
Pfizer 3Efficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype3190, 4949
Takeda2Interventions for Fatigue in Inflammatory Bowel Disease 3246
Pfizer3Predicting Antidepressant Response in Children and Adolescents with Depression3360
Pfizer3A Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases5086
Pfizer1Predictors of therapeutic and adverse effects of medicines used in the treatment of gastrointestinal cancers5290
Pfizer1Risk of small for gestational age (SGA) after malaria in pregnancy using the Intergrowth 21st birth weight chart compared to a local weight chart as reference: A meta-analysis of individual participant level data5949
Eli Lilly1Interferon (IFN) signatures as predictive markers of sensitivity to CDK4/6i in breast cancer6026
Pfizer1The Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled Analysis6594
Boehringer Ingelheim1Genetic Correlation between stroke recurrence in patients treated with dabigatran and dabigatran plasma levels6628
Pfizer1Analgesic medicines for adults with low back pain: a systematic review and network meta-analysis6689
AbbVie1Identification of gene co-expression networks regulated by Interleukin-12 in RNA-sequencing data comparing skin biopsies form Ustekinumab and Risankizumab treated psoriasis patients7134
Pfizer1A Bayesian Exact Platform Design for Multi-arm trials with Concurrent or Historical Controls COVID7278
Boehringer Ingelheim1What are the re-identification risk scores of publicly available anonymised clinical trial datasets?7400
Takeda1A matching-adjusted indirect treatment comparison of personalised prophylaxis therapy (Nuwiq vs. Adynovate) in patients with hemophilia A7499
AbbVie2Post hoc Statistical analyses and Simulations to explore various statistical methods for clinical response data in Hidradenitis Suppurativa using Pioneer 1 and 2 individual patient data for Adalimumab8386
Lilly2Tumor Growth Inhibition-Overall Survival (TGI-OS) model development and validation for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer8563
Roche1Machine Learning methods for survival prediction from longitudinal circulating tumor DNA data during first-line treatment of metastatic Non-Squamous Non-Small Cell Lung Cancer9036
Bristol Myers Squibb4Randomized Controlled Trial Data Availability and Re-Analysis Project7401
Roche1longitudinal circulating tumor DNA-based model associated with survival9080
Ipsen1Pain Reduction With AbobotulinumtoxinA for the Treatment of Hallux Valgus in Adult Participants: Results of a Randomized and Placebo-Controlled Phase 2 Trial--- A Closer Look.9289
AstraZeneca1Optimal estimation of the number of subjects in clinical trials to improve the quality of clinical research and the development of new treatments for cancer patients8833
Boehringer Ingelheim2A combined proteomics and machine learning approach to identify therapy response in prevention of heart failure in individuals at risk9386
Bristol Myers Squibb1Biomarker study of nivolumab combination therapy as 1st line treatment for esophageal cancer in our hospital (CheckMate 648)8574
Pfizer2Relationship of Changes in Coronary Artery Atherosclerosis Measurement and Major Cardiovascular Events in Randomized Clinical Trials9436
Regeneron1Relationship of Changes in Coronary Artery Atherosclerosis Measurement and Major Cardiovascular Events in Randomized Clinical Trials9436
Bristol Myers Squibb1Relationship of Changes in Coronary Artery Atherosclerosis Measurement and Major Cardiovascular Events in Randomized Clinical Trials9436

Reason Data Request Denied: The Data Request required data that was not collected in the studies

Data contributorStudies Research ProposalRequest ID
Boehringer Ingelheim7Patterns and predictors of toxicity with afatinib for treatment of patients with advanced EGFR mutant NSCLC4325
Biogen1Inferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platforms 6055
AstraZeneca6A systematic review of the steroid sparing effect of biologicals in severe asthma6524
Biogen1The effects of systemic anti-infective concomitant medications on progression of neurological diseases7143
Takeda1The effects of systemic anti-infective concomitant medications on progression of neurological diseases7143
Boehringer Ingelheim1In patients with multi-territory acute ischaemic stroke, do direct oral anticoagulants (DOACs) reduce the risk of future stroke: RE-SPECT ESUS substudy7478
Pfizer3Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis7549
Boehringer Ingelheim1Exploration of ailments related to back pain in the medical history data from clinical studies of healthy subjects using formal hypothesis testing and data mining7598
Bayer1The Impact of Enzalutamide and Darolutamide on Sexual Function in Men with Advanced Prostate Cancer8696
Lilly6The impact of human epidermal growth factor receptor 2-low (HER2-low) Expression on the Efficacy of endocrine therapy in Hormone Receptor-positiveHER2-Negative (HR+HER2-) Breast Cancer8856

Reason Data Request Denied: The Data Request's project aim is commercial or litigious and The Data Request is out of scope

Data ContributorStudiesResearch ProposalRequest ID
Pfizer6Data grant application of completed neuropathic pain clinical trials using pregabalin (Lyrica®) to validate the Quantitative Data Surveillance System (QDSS)4336
Pfizer16Role of clinical, historical and demographic factors in the response to antidepressants versus placebo7541
GlaxoSmithKline1Development of a model to simulate the pharmacokinetics of drugs in patients with different characteristics to advance precision medicine9486

Reason Data Request Denied: Data collected subject to legal, contractual or consent provisions that prevent further sharing of clinical data

Data contributorStudies Research ProposalRequest ID
Daiichi-Sankyo1Exploring Tripartite Estimands approach – Reanalysis of actual clinical trials to estimate the treatment effect for Clinical Trials5328
GlaxoSmithKline4Developing a Generalizable Blockchain Architecture to Enhance Clinical Trial Recruitment and Achieve Persistent Monitoring6501
Bristol-Myers Squibb2Including real-world data from expanded access programs into regulatory approval decisions and health-economic analyses: benefits and challenges5351
AstraZeneca2An individual participant data meta-analysis to evaluate PD1 vs PD-L1 Inhibitors in Asian subgroup Cancer patients7824

Reason Data Request Denied: The data contributor or sponsor doesn't have the legal authority to provide the data

Data ContributorStudiesResearch ProposalRequest ID
Boehringer Ingelheim1Tolerability of duloxetine in the elderly and in adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placebo.4112
Pfizer2Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies 5924
Pfizer1Baseline ischemic stroke risk and heterogeneity of relative and absolute benefit of statin therapy: a secondary analysis of the SPARCL trial7869
Pfizer1Alternative methods to summarize Low Density Lipoprotein Cholesterol over time in the SPARCL trial8237
Pfizer5Add-on treatment for refractory focal-onset epilepsy: Individual Participant Data Network Meta-analysis7227
Pfizer1Stratification of urothelial cancer mutations to improve the prediction of the tumor response to checkpoint inhibitors8431
Pfizer1Evaluation of on-treatment inflammatory biomarker as early predictors of response to avelumab maintanance in urothelial cancer8545
Pfizer1Effect of Prior Local Therapy on Response to First Line Systemic Therapy in Men with Metastatic Castrate Resistant Prostate Cancer8714
Pfizer1The impact of long-term proton pump inhibitors use on the prognosis of patients receiving Androgen-annihilation therapy8577
Pfizer3Anemia and therapy with Janus Kinase Inhibitors in patients with ulcerative colitis8688
Pfizer1Assessing the Androgen indifferent prostate cancer patients reponse to novel antiandrogen-based regimen or taxanes.8722

Reason Data Request Denied: The Data Request competes with the data contributor/sponsor's publication plan

Data ContributorStudiesResearch ProposalRequest ID
Boehringer Ingelheim1The Effectiveness of a Software in Pulmonary Fibrosis Staging and Severity Evaluation in Idiopathic Pulmonary Fibrosis (IPF) Patients6631
Daiichi Sankyo1Big data and meta-analytic approaches for better phenotyping in atrial fibrillation and heart failure6541
Boehringer Ingelheim1Predictors of recurrent stroke in patients after embolic stroke of undetermined source (ESUS) treated with dabigatran7429
Biogen13Validation of surrogate endpoints and development of models for predicting outcomes and treatment response in relapsing-remitting multiple sclerosis patients5573
GlaxoSmithKline9Role of clinical, historical and demographic factors in the response to antidepressants versus placebo7541
Boehringer Ingelheim1Exploration of clinical outcomes in idiopathic pulmonary fibrosis and treatment response to Nintedanib by monocyte count at enrolment7859
Daiichi Sankyo1Summarising the therapeutic and adverse effects of antibody-drug conjugates in older women with breast cancer: A review of clinical trial individual-participant data8056
Bayer1The effect of finerenone on serum potassium in patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease in the FIDELIO-DKD clinical trial8565
Bayer1Effect of Prior Prostate Directed Local Therapy on Response to First Line Androgen Receptor Axis Targeted Therapy in Non-metastatic Castrate Resistant Prostate Cancer: Exploratory Analysis of ARAMIS Trial8801
Bayer1Predictors of hyperkalemia and worsening renal function with finerenone vs eplerenone: findings from ARTS-HF trial8691
Boehringer Ingelheim1The Effect of Beta Blocker Use in heart Failure with Preserved Ejection Fraction. A secondary analysis of the Emperor Preserved trial8861
Boehringer Ingelheim1Machine learning-based identification of the target population for Empagliflozin given its heterogeneous treatment effect: a post-hoc analysis of the EMPA-REG OUTCOME, EMPEROR-REDUCED, and EMPEROR-PRESERVED trials8934
Daiichi Sankyo1Population pharmacokinetic, pharmacodynamic and clinical outcome analysis in patients with HER-2 positive breast cancer receiving trastuzumab deruxtecan9276
Boehringer Ingelheim1Efficacy and Safety of Obinutuzumab in Connective Tissue Disease-Related Interstitial Lung Disease (OCTILIA)9409
Boehringer Ingelheim1Machine learning-based identification of the mechanism of empagliflozin for cardiorenal protection: a post-hoc analysis of the EMPA-REG OUTCOME, EMPEROR-REDUCED, and EMPEROR-PRESERVED trials9477

Reason Data Request Denied: The Data Request's project aim is commercial or litigious

Data ContributorStudiesResearch ProposalRequest ID
Pfizer4Enhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative Colitis4041
GSK10Using Artificial Intelligence to Personalize Treatment Selection and Trajectory Monitoring of Bipolar Disorder7811
Sunovion2Using Artificial Intelligence to Personalize Treatment Selection and Trajectory Monitoring of Bipolar Disorder7811

Reason Data Request Denied: The data requested cannot be shared due to ongoing regulatory activities

Data ContributorStudiesResearch ProposalRequest ID
AstraZeneca1Validation of a Machine Learning-based Model to Predict the Risk of Heart Failure among Patients with Diabetes Mellitus: the WATCH-DM Risk Score6522
AstraZeneca1Development and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD)6712
Pfizer1Determining the impact of Tafamidis on weight loss and cachexia development in Transthyretin amyloidosis (ATTR) patients based on the ATTR-ACT trial (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTR-ACT)7286
Sanofi1A new covariate randomization method for multi-arm randomized controlled trials7782
Daiichi Sankyo1Randomized Controlled Trial Data Availability and Re-Analysis Project7401
Pfizer1Assessing associations between 6-minute walk distance (6MWD) outcomes, patient-reported outcomes, and clinical outcomes in patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)9037
AstraZeneca1Reduction of residual cardiometabolic risk in healthy people for the prevention of cardiovascular diseases: a data-driven analysis of the JUPITER trial8994

Reason Data Request Denied: The Data Request did not meet the data contributor/sponsor policies for informed consent

Data ContributorStudiesResearch ProposalRequest ID
Bristol Myers Squibb2A survival extrapolation study of ipilimumab + dacarbazine (IPIflDTIC) versus placebo + dacarbazine (PBOflDTIC) in melanoma patients in NCT00324155 trial: using flexible parametric relative survival models6859
AstraZeneca1Treatment with multi-drug regimens combining Mitogen-activated protein Kinase targeted therapy and immunotherapy in melanoma6709
Bristol Myers Squibb1Validation of a new model of anticoagulant effect in patients with atrial fibrillation7397
Bristol Myers Squibb1Dose reduction and discontinuation of disease modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis7427
Bristol Myers Squibb1Disease‐modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient data8728

Reason Data Request Denied: The Data Request's research proposal lacks clear scientific merit

Data ContributorStudiesResearch ProposalRequest ID
Pfizer5Data-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on European Public Assessment Reports5853
Regeneron1Data-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on European Public Assessment Reports5853
Regeneron3Recruitment and treatment outcomes of racial subgroups in Phase III clinical trial data evaluating diabetic macular edema and retinal vein occlusion.6688
Medical Research council1Independent Integrity Checking of Clinical Trials7314
Pfizer2The Impact of Second Generation Anti-Androgens on Sexual Function in Men with Advanced Prostate Cancer7316
Pfizer6Predictors of therapeutic and adverse effects of medicines used in the treatment of prostate cancer5967
Regeneron1The Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled Analysis6594
Regeneron4Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours
7667
AstraZeneca5Efficacy comparison of biologics (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) in treatment of severe eosinophilic asthma — a network meta-analysis7274
Pfizer2The Impact of Second Generation Anti-Androgens on Quality of Life in Men with Advanced Prostate Cancer7506
Regeneron4Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatment7595
Takeda1Patient reported outcomes in cutaneous T-cell lymphoma8715
Regeneron2Randomized Controlled Trial Data Availability and Re-Analysis Project7401

Reason Data Request Denied: The data requested is not appropriate for the research proposal in the Data Request

Data ContributorStudiesResearch ProposalRequest ID
Boehringer Ingelheim3Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of non–small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)

6629
Pfizer1Machine learning for personalized prediction of enzalutamide treatment outcomes in nonmetastatic castration-resistant prostate cancer7386
Pfizer2The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcome of patients with hormone receptor positive, HER2-negative, advanced breast cancer7596
Boehringer Ingelheim2Evaluating Clinical Trial Data Conventions for the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM)6869
Boehringer Ingelheim2Development of novel statistical methods to detect treatment effect in Alzheimer’s disease clinical trials over time8438
Regeneron1AVID: Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis7852
Lilly3Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancer8180
AbbVie1Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes8244
AstraZeneca8Cutaneous adverse effects of immunotherapy medications in the treatment of cancers and their associations with overall survival7857
Pfizer1Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)6762
Lilly5Clinical and molecular characteristics of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer a meta-analysis8842
AstraZeneca4The efficacy of programmed cell death protein 1 (PD-1)programmed death-ligand 1 (PD-L1) inhibitors in solid tumor patients with different clinicopathological characteristics a meta-analysis8921
Tempus Labs3Classifiers for studying head and neck tumors using multi-omics9855
AstraZeneca1Characterizing checkpoint inhibitor pneumonitis durvalumab in patients with unresectable stage III Non-small Cell Lung Cancer (NSCLC)9287

Reason Data Request Denied: There is a reasonable likelihood that a patient could be re-identified

Data ContributorStudiesResearch ProposalRequest ID
AstraZeneca2Unraveling response to immunotherapy in advanced non-small cell lung cancer using circulating tumor deoxyribonucleic acid7293
GlaxoSmithKline1Examining Variability in Data Elements and Populations in Multiple Sclerosis Clinical Trials Data - Development of Analytic and Visualization Approaches5544
Roche1Genetic determinants of immunotherapy outcome in kidney cancer7812
Sanofi2Efficacy and safety of enzyme replacement therapy and chaperone Migalastat for Anderson-Fabry disease: a systemic review and meta-analysis of randomized controlled trials8915

Reason Data Request Denied: The data requested is unavailable

Data ContributorStudiesResearch ProposalRequest ID
Biogen12Examining Variability in Data Elements and Populations in Multiple Sclerosis Clinical Trials Data - Development of Analytic and Visualization Approaches5544
Boehringer Ingelheim1Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancer8180
Bayer1Androgen receptor mutations and response to Darolutamide in non-metastatic castrate resistant prostate cancer patients9117
Boehringer Ingelheim2Effect of Calcium Channel Blocker Therapy in Idiopathic Pulmonary Fibrosis8815

Reason Data Request Denied: The data requested cannot be shared due to ongoing business activities

Data ContributorStudiesResearch ProposalRequest ID
AstraZeneca9Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatment7595

Reason Data Request Denied: Potential conflict of interest, and a potential competitive risk

Data ContributorStudiesResearch ProposalRequest ID
Taiho1Prevalence and treatment of long delayed (>120 hours) chemotherapy-induced nausea and vomiting (CINV) – a systematic review and individual patient-data meta-analysis8651
Pfizer6Understanding the biological mechanisms related to episodes of rapid onset osteoarthritis (RPOA) to support the development of appropriate biomarkers of risk.9283
AbbVie1Predicting survival in chronic lymphocytic leukaemia from measurable residual disease (MRD) kinetics8839
AbbVie1Evaluate disease trajectories using patient level data in an independent dataset to confirm a previous analysis based on adalimumab patients enrolled in VARSITY9856
GlaxoSmithKline1Cognitive factors as predictors of treatment outcomes in patients with Schizophrenia9373
Sumitomo1Cognitive factors as predictors of treatment outcomes in patients with Schizophrenia9373

Reason for Denial of Studies in a Data Request

Data contributorStudies Reason of Non-ApprovalResearch ProposalRequest ID
Pfizer2The Data Requested is out of scope of data sharing policyIdentification of Research Common Data Elements in HIV/AIDS using data science methods 3244
Pfizer1The Data requested is unavailablePredicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis 3369
Boehringer Ingelheim1Document not available in EnglishRisk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation 3876
Eli Lilly5The data contributor or sponsor doesn't have the legal authority to provide the dataTolerability of duloxetine in the elderly and in adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placebo.4112
Boehringer Ingelheim2The data requested is not appropriate for the research proposal in the Data RequestPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer5289
UCB1Data collected subject to legal, contractual or consent provisions that prevent further sharing of clinical dataAntiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysis5291
AbbVie1There is a reasonable likelihood that a patient could be re-identifiedSharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator - Data and Analytics Platform for Analysis of Outcome Measures and Other Purposes5989
Roche1The Data Requested is out of scope of data sharing policyPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer5289
Pfizer1The data requested is unavailableComparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysis4324
Pfizer3The data requested is unavailableInferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platforms6055
Boehringer Ingelheim1The data contributor or sponsor doesn't have the legal authority to provide the dataAssessing heterogeneity in relative treatment efficacy by age, sex and comorbidity.5483
GlaxoSmithKline1The data requested is unavailableTositumomab: statistical modeling of expanded access programs and conventional trials6477
AbbVie1There is a reasonable likelihood that a patient could be re-identified (due to the very small number of patients)Exploring the heterogeneity of cognitive profile in patients with Progressive Supranuclear Palsy (PSP) enrolled in the ABBV-8E12 trial and the relationship to brain volumes7147
AstraZeneca1The Data Request competes with the data contributor/sponsor's publication/dissemination planEvaluation of available statistical methods performance under non-proportional hazards6483
Roche2The data requested is unavailablePredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer5289, 6499
AstraZeneca1Out of Scope of Data Contributor’s Data Sharing PolicyPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer5289, 6499
UCB1Data collected subject to legal, contractual or consent provisions that prevent further sharing of clinical dataReal time monitoring of individual response to antiseizure medication treatment during clinical trials7161
Roche2Studies where data sharing is prohibited by the consent, legal, regulatory, or contractual constraints on data sharing.Evaluating the association between proteinuria and thrombosis and its predictors in patients treated with Bevacizumab6066
Abbvie1The data requested is not appropriate for the research proposal in the Data RequestDisease‐modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient data5987
AstraZeneca1Studies where data sharing is prohibited by the consent, legal, regulatory, or contractual constraints on data sharingExploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomes
6593
AstraZeneca4Study cannot be shared this time due to ongoing regulatory activitiesSummarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours7667
Pfizer3The data requested is not appropriate for the research proposal in the Data RequestSummarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours7667
AstraZeneca1The data requested cannot be shared due to ongoing regulatory activitiesEvaluating Clinical Trial Data Conventions for the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM)6869
GlaxoSmithKline1The Data Request required data that was not collected in the studies requestedEvaluating Clinical Trial Data Conventions for the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM)6869
UCB1The Data Request did not meet the data contributor/sponsor policies for informed consentWhat are the re-identification risk scores of publicly available anonymised clinical trial datasets?7400
UCB1The data contributor or sponsor doesn't have the legal authority to provide the dataAdd-on treatment for refractory focal-onset epilepsy: Individual Participant Data Network Meta-analysis7227
Roche1Data Sharing is prohibited by the consent, legal, regulatory, or contractual constraints on data sharingPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer6499
AstraZeneca1Document not available in EnglishLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of non–small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)6629
Pfizer1Out of scope since the indication is not approved in US or EUSPondyloarthritis EARly Definition (ASAS-SPEAR) Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials7828
Pfizer1The data requested is unavailableSPondyloarthritis EARly Definition (ASAS-SPEAR) Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials7828
Takeda1The data requested is not appropriate for the research proposal in the Data RequestThe prognostic value of faecal calprotectin for long-term outcomes in ulcerative colitis8266
Pfizer1The Data Requested is out of scope of data sharing policyAddressing the synergistic effect of metformin in patients with Pancreatic neuroendocrine tumors treated with sunitinib: a post-hoc analysis from the main pivotal trials.7874
Roche1Studies where data sharing is prohibited by the consent, legal, regulatory, or contractual constraints on data sharingOrgan-specific metastatic landscape dissects programmed death ligand-1 (PD-L1) blockade efficacy in advanced cancer8557
Pfizer1Out of scope for data sharing because the indication is not approved in US or EUSystemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials7620
GSK5Clinical studies where data labels and/or supporting documents are not in EnglishHeterogenous Effects in Diabetes Mellitus Clinical Trials and Implications for Physician Prescriptions7759
Pfizer4The data contributor or sponsor doesn't have the legal authority to provide the dataRandomized Controlled Trial Data Availability and Re-Analysis Project7401
Bristol Myers Squibb3The Data Requested is out of scope of data sharing policy Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)6762
Pfizer2The Data requested is unavailableValidating a Personalised Ankylosing Spondylitis Metrology Index8576
AstraZeneca3The data requested is not appropriate for the research proposal in the Data RequestClinical and molecular characteristics of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer a meta-analysis8842
AstraZeneca6The data requested is not appropriate for the research proposal in the Data RequestThe impact of human epidermal growth factor receptor 2-low (HER2-low) Expression on the Efficacy of endocrine therapy in Hormone Receptor-positiveHER2-Negative (HR+HER2-) Breast Cancer8856
Boehringer ingelheim1The Data Request competes with the data contributor/sponsor's publication planThe impact of malnutrition on the Efficacy and Safety of empagliflozin for heart failure With reduced ejection fraction8850
Biogen1The data cannot be shared due to ongoing regulatory activities;Monitoring of upper extremity motor function in Multiple Sclerosis the nine-hole-peg-test in MS revisited9132